Unicycive Therapeutics, Inc. (NasdaqCM: UNCY)
Health Care · Biotechnology · US
$4.07
-3.55% today · -8.3% 1Y
Unicycive Therapeutics, Inc. (NasdaqCM: UNCY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $117.55M and employs 21 people.
Over the last twelve months the share price has lost 8.3%, trading between 3.93 and 8.74.
Tweenvest scores Unicycive Therapeutics, Inc. across four factors: quality 37/100, value 64/100. Its strongest factor is value.
UNCY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $117.55M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.56
- Dividend yield
- —
- Beta (5Y)
- 1.82
- 52-week high
- $8.74
- 52-week low
- $3.93
- Avg volume (3M)
- —
- Shares outstanding
- 27.86M
- Employees
- 21
- Next earnings
- —
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
- ISIN
- US90466Y2028
- Founded
- 2016
- Listed since
- Jul 12, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Foghorn Therapeutics Inc.NasdaqGM: FHTX | $119.96M | $1.99 | -1.49% |
| Corbus Pharmaceuticals Holdings, Inc.NasdaqCM: CRBP | $118.56M | $5.27 | -14.03% |
| Nykode Therapeutics ASOB: NYKD | $117.88M | Nkr3.40 | -2.16% |
| Aroa Biosurgery LimitedASX: ARX | $117.80M | AU$0.49 | -3.92% |
| Quantum Cyber N.V.NasdaqCM: QUCY | $116.85M | $1.39 | -2.80% |
| Great Novel Therapeutics Biotech & MedicalsTPEX: 7427 | $116.78M | NT$70.30 | -0.85% |
| ISU Abxis Co., Ltd.KOSDAQ: A086890 | $116.41M | ₩3,845.00 | +9.08% |
| 4basebio PLCAIM: 4BB | $115.64M | £5.63 | 0.00% |
Figures last refreshed Oct 4, 2026.